vs
Side-by-side financial comparison of MARCHEX INC (MCHX) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
MARCHEX INC is the larger business by last-quarter revenue ($10.8M vs $9.1M, roughly 1.2× Protalix BioTherapeutics, Inc.). MARCHEX INC runs the higher net margin — -21.4% vs -60.3%, a 39.0% gap on every dollar of revenue. On growth, MARCHEX INC posted the faster year-over-year revenue change (-9.0% vs -49.9%). Over the past eight quarters, MARCHEX INC's revenue compounded faster (-3.2% CAGR vs -6.7%).
Marchex Inc. is a U.S.-headquartered technology company focused on conversational analytics, call tracking, and digital marketing solutions for small and medium-sized businesses as well as enterprise clients across North America. Its core products help businesses optimize customer acquisition strategies, quantify marketing campaign performance, and improve customer engagement across voice and digital communication channels.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MCHX vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.8M | $9.1M |
| Net Profit | $-2.3M | $-5.5M |
| Gross Margin | 61.6% | 49.4% |
| Operating Margin | -21.9% | -51.1% |
| Net Margin | -21.4% | -60.3% |
| Revenue YoY | -9.0% | -49.9% |
| Net Profit YoY | -21.3% | -184.8% |
| EPS (diluted) | $-0.05 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.8M | $9.1M | ||
| Q3 25 | $11.5M | $17.9M | ||
| Q2 25 | $11.7M | $15.7M | ||
| Q1 25 | $11.4M | $10.1M | ||
| Q4 24 | $11.9M | $18.2M | ||
| Q3 24 | $12.6M | $18.0M | ||
| Q2 24 | $12.1M | $13.5M | ||
| Q1 24 | $11.6M | — |
| Q4 25 | $-2.3M | $-5.5M | ||
| Q3 25 | $-1.0M | $2.4M | ||
| Q2 25 | $84.0K | $164.0K | ||
| Q1 25 | $-2.0M | $-3.6M | ||
| Q4 24 | $-1.9M | $6.5M | ||
| Q3 24 | $-831.0K | $3.2M | ||
| Q2 24 | $-756.0K | $-2.2M | ||
| Q1 24 | $-1.4M | — |
| Q4 25 | 61.6% | 49.4% | ||
| Q3 25 | 63.1% | 53.4% | ||
| Q2 25 | 65.1% | 62.5% | ||
| Q1 25 | 63.3% | 19.1% | ||
| Q4 24 | 63.2% | 78.7% | ||
| Q3 24 | 66.4% | 53.4% | ||
| Q2 24 | 65.6% | 29.8% | ||
| Q1 24 | 61.9% | — |
| Q4 25 | -21.9% | -51.1% | ||
| Q3 25 | -8.2% | 11.9% | ||
| Q2 25 | -4.6% | 7.5% | ||
| Q1 25 | -16.4% | -41.0% | ||
| Q4 24 | -13.3% | 39.6% | ||
| Q3 24 | -6.6% | 22.2% | ||
| Q2 24 | -6.0% | -18.0% | ||
| Q1 24 | -11.3% | — |
| Q4 25 | -21.4% | -60.3% | ||
| Q3 25 | -8.9% | 13.2% | ||
| Q2 25 | 0.7% | 1.0% | ||
| Q1 25 | -17.4% | -35.8% | ||
| Q4 24 | -16.0% | 35.6% | ||
| Q3 24 | -6.6% | 18.0% | ||
| Q2 24 | -6.3% | -16.4% | ||
| Q1 24 | -12.5% | — |
| Q4 25 | $-0.05 | $-0.06 | ||
| Q3 25 | $-0.02 | $0.03 | ||
| Q2 25 | $0.00 | $0.00 | ||
| Q1 25 | $-0.05 | $-0.05 | ||
| Q4 24 | $-0.04 | $0.10 | ||
| Q3 24 | $-0.02 | $0.03 | ||
| Q2 24 | $-0.02 | $-0.03 | ||
| Q1 24 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.9M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $30.1M | $48.2M |
| Total Assets | $39.7M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $14.7M | ||
| Q3 25 | $10.3M | $13.6M | ||
| Q2 25 | $10.5M | $17.9M | ||
| Q1 25 | $10.0M | $19.5M | ||
| Q4 24 | $12.8M | $19.8M | ||
| Q3 24 | $12.1M | $27.4M | ||
| Q2 24 | $12.0M | $23.4M | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $30.1M | $48.2M | ||
| Q3 25 | $31.9M | $52.9M | ||
| Q2 25 | $32.0M | $49.9M | ||
| Q1 25 | $31.4M | $45.2M | ||
| Q4 24 | $32.6M | $43.2M | ||
| Q3 24 | $34.1M | $32.4M | ||
| Q2 24 | $34.5M | $28.6M | ||
| Q1 24 | $34.9M | — |
| Q4 25 | $39.7M | $82.3M | ||
| Q3 25 | $41.1M | $82.3M | ||
| Q2 25 | $42.0M | $78.5M | ||
| Q1 25 | $40.6M | $73.9M | ||
| Q4 24 | $43.2M | $73.4M | ||
| Q3 24 | $44.1M | $61.6M | ||
| Q2 24 | $45.5M | $91.5M | ||
| Q1 24 | $45.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $121.0K | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $121.0K | $2.0M | ||
| Q3 25 | $290.0K | $-3.7M | ||
| Q2 25 | $803.0K | $-5.2M | ||
| Q1 25 | $-2.6M | $-5.1M | ||
| Q4 24 | $875.0K | $4.0M | ||
| Q3 24 | $382.0K | $4.1M | ||
| Q2 24 | $117.0K | $-3.6M | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $757.0K | $3.6M | ||
| Q3 24 | $199.0K | $4.0M | ||
| Q2 24 | $40.0K | $-3.8M | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | 6.3% | 19.6% | ||
| Q3 24 | 1.6% | 22.4% | ||
| Q2 24 | 0.3% | -28.1% | ||
| Q1 24 | -21.4% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 1.0% | 2.3% | ||
| Q3 24 | 1.5% | 0.5% | ||
| Q2 24 | 0.6% | 1.3% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | 9.56× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MCHX
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
